Recombinant Human ATP-dependent DNA helicase Q1 (RECQL)

The production of this Recombinant Human VP35 protein began at the genetic level, where the coding sequence for the VP35 protein was first isolated and cloned into an expression plasmid vector. Recombinant DNA technology was used in the process. Next step was cloning. The expression vector must be introduced into the host cell (E.coli) so that the cells could be cultured and expressed the desired RECQL protein. And we finally got the recombinant RECQL protein with the purity of 85%+ determined by SDS-PAGE. Active adenosine triphosphate (ATP) is required for inflammasome activation. Intracellular ATP is released after cellular stress and/or activation, and purinergic signaling has been shown to modulate inflammation and immunity. In the extracellular space, ATP is rapidly hydrolysed in a stepwise manner to ADP, AMP (adenosine monophosphate) and adenosine by ectoenzymes. Extracellular ATP (eATP) signals through both ATP-gated ion channels P2X and G protein-coupled receptor (GPCR) P2Y membrane receptors, whereas ADP signals through P2Y receptors and adenosine through P1 receptors (or A receptors). Extracellular adenosine level is the result of adenosine production from extracellular ATP and ADP, its degradation into inosine and its reuptake by cells. Both ATP and adenosine can be transported outside of the cell via diffusion or active transport, whereas only adenosine can enter the cells through adenosine transporters. Intracellular adenosine is converted to ATP via phosphorylation steps mediated by adenosine kinase (AK) and AMP kinase (AMPK). ATP-derived adenosine and its subsequent signalling through P1 receptors have beneficial roles in acute disease states.